FDA
-
-
-
-
-
-
-
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
-
-
-
-
-
-
-
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
-
-
-
-
-
-
-
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
-
-
-
-
-
-
-
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
-
-
-
-
-
-
-
Innate Pharma (IPHA) Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study
-
-
-
-
-
-
-
Innate Pharma Reports Full Year 2020 Financial(1) Results and Business Update
-
-
-
-
-
-
-
Innate Pharma to Participate in upcoming investor conferences
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

